Loading stock data…
$1.87+0.02 (+1.08%)
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
Foghorn Therapeutics Inc. in the Healthcare sector is trading at $1.84 with a market capitalization of $246M. Wall Street consensus targets $4.17 (6 analysts), implying a +126.4% move over the next 12 months. The stock is currently near its 52-week low of $1.79, remaining 62.6% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $16.07M↑ | $3.27M↓ | $9.25M↑ | $8.15M↑ | $7.56M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$8.80M↑ | -$21.57M↓ | -$19.60M↓ | -$18.50M↑ | -$21.10M |
| Net Income | -$7.19M↑ | -$19.88M↑ | -$21.66M↓ | -$15.85M↑ | -$17.94M |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses i...